Skip to main navigation Skip to search Skip to main content

Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies

  • Ann E Davidson
  • , Fazeel M Siddiqui
  • , Michael A Lopez
  • , Peter Lunt
  • , Heather A Carlson
  • , Brian E Moore
  • , Seth Love
  • , Donald E Born
  • , Helen Roper
  • , Anirban Majumdar
  • , Suman Jayadev
  • , Hunter R Underhill
  • , Corrine O Smith
  • , Maja von der Hagen
  • , Angela Hubner
  • , Philip Jardine
  • , Andria Merrison
  • , Elizabeth Curtis
  • , Thomas Cullup
  • , Heinz Jungbluth
  • Mary O Cox, Thomas L Winder, Hossam Abdel Salam, Jun Z Li, Steven A Moore, James J Dowling

Research output: Contribution to journal › Article (Academic Journal) › peer-review

51 Citations (Scopus)

Abstract

The β-tropomyosin gene encodes a component of the sarcomeric thin filament. Rod-shaped dimers of tropomyosin regulate actin-myosin interactions and β-tropomyosin mutations have been associated with nemaline myopathy, cap myopathy, Escobar syndrome and distal arthrogryposis types 1A and 2B. In this study, we expand the allelic spectrum of β-tropomyosin-related myopathies through the identification of a novel β-tropomyosin mutation in two clinical contexts not previously associated with β-tropomyosin. The first clinical phenotype is core-rod myopathy, with a β-tropomyosin mutation uncovered by whole exome sequencing in a family with autosomal dominant distal myopathy and muscle biopsy features of both minicores and nemaline rods. The second phenotype, observed in four unrelated families, is autosomal dominant trismus-pseudocamptodactyly syndrome (distal arthrogryposis type 7; previously associated exclusively with myosin heavy chain 8 mutations). In all four families, the mutation identified was a novel 3-bp in-frame deletion (c.20_22del) that results in deletion of a conserved lysine at the seventh amino acid position (p.K7del). This is the first mutation identified in the extreme N-terminus of β-tropomyosin. To understand the potential pathogenic mechanism(s) underlying this mutation, we performed both computational analysis and in vivo modelling. Our theoretical model predicts that the mutation disrupts the N-terminus of the α-helices of dimeric β-tropomyosin, a change predicted to alter protein-protein binding between β-tropomyosin and other molecules and to disturb head-to-tail polymerization of β-tropomyosin dimers. To create an in vivo model, we expressed wild-type or p.K7del β-tropomyosin in the developing zebrafish. p.K7del β-tropomyosin fails to localize properly within the thin filament compartment and its expression alters sarcomere length, suggesting that the mutation interferes with head-to-tail β-tropomyosin polymerization and with overall sarcomeric structure. We describe a novel β-tropomyosin mutation, two clinical-histopathological phenotypes not previously associated with β-tropomyosin and pathogenic data from the first animal model of β-tropomyosin-related myopathies.
Original languageEnglish
Pages (from-to)508-21
Number of pages14
JournalBrain
Volume136
Issue numberPt 2
DOIs
Publication statusPublished - Feb 2013

Research Groups and Themes

  • Cerebrovascular and Dementia Research Group

Keywords

  • Young Adult
  • Animals
  • Humans
  • Lysine
  • Amino Acid Sequence
  • Child
  • Zebrafish
  • Tropomyosin
  • Muscular Diseases
  • Adult
  • Molecular Sequence Data
  • Middle Aged
  • Adolescent
  • Female
  • Male
  • Sequence Deletion

Fingerprint

Dive into the research topics of 'Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies'. Together they form a unique fingerprint.

Cite this